Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
School of Pharmacy, Research Triangle Park, NC, USA.
Psychopharmacology (Berl). 2024 Dec;241(12):2453-2469. doi: 10.1007/s00213-024-06690-x. Epub 2024 Sep 27.
G-protein biased mu-opioid receptor (MOR) agonists have been reported to exhibit superior therapeutic windows compared to prototypical MOR agonists when relating antinociception to respiratory depression. However, there is relatively little research on the abuse potential of G-protein biased MOR agonists in relation to other behavioral endpoints.
The aim of the present study was to quantitatively compare the reinforcing, antinociceptive, and respiratory-depressant effects of the prototypical MOR agonists, fentanyl and oxycodone, to the G-protein biased MOR agonists, SR14968 and SR17018, in male and female rats.
In the self-administration study, four separate groups of Sprague-Dawley (SD) rats self-administered intravenous (i.v.) fentanyl, oxycodone, SR14968, and SR17018 under a progressive-ratio schedule of reinforcement. Using a within-subjects design, separate cohorts of SD rats were tested with i.v. fentanyl, oxycodone, SR14968, and SR17018 using a hot-plate assay, assays of neuropathic and inflammatory antinociception, and whole-body plethysmography.
All MOR agonists functioned as reinforcers, but SR14968 and SR17018 were less efficacious relative to oxycodone and fentanyl. Moreover, all MOR agonists produced dose-dependent and fully efficacious antinociception across all nociception modalities. Oxycodone and fentanyl, but not SR14968 or SR17018, produced respiratory depression in a dose-dependent manner.
The present results indicate that the G-protein biased MOR agonists tested herein produce MOR-typical antinociception, exhibit reduced but apparent abuse potential, and do not produce respiratory effects at doses that are above the antinociceptive range. Atypical MOR agonists within the SR series should be further studied as foundational molecules for the development of safter analgesics.
与呼吸抑制相关时,G 蛋白偏向性 μ 阿片受体(MOR)激动剂被报道显示出比原型 MOR 激动剂更好的治疗窗口。然而,关于 G 蛋白偏向性 MOR 激动剂相对于其他行为终点的滥用潜力的研究相对较少。
本研究的目的是定量比较原型 MOR 激动剂芬太尼和羟考酮与 G 蛋白偏向性 MOR 激动剂 SR14968 和 SR17018 在雄性和雌性大鼠中的强化、镇痛和呼吸抑制作用。
在自我给药研究中,四组不同的 Sprague-Dawley(SD)大鼠根据递增比率强化方案自行静脉(i.v.)给予芬太尼、羟考酮、SR14968 和 SR17018。使用 i.v. 芬太尼、羟考酮、SR14968 和 SR17018 进行 within-subjects 设计,使用热板测定法、神经病理性和炎症性镇痛测定法和全身 plethysmography 对单独的 SD 大鼠进行测试。
所有 MOR 激动剂均作为强化物起作用,但 SR14968 和 SR17018 的效力相对低于羟考酮和芬太尼。此外,所有 MOR 激动剂在所有疼痛模式下均产生剂量依赖性和完全有效的镇痛作用。羟考酮和芬太尼,但不是 SR14968 或 SR17018,以剂量依赖性方式产生呼吸抑制。
本研究结果表明,本文测试的 G 蛋白偏向性 MOR 激动剂产生 MOR 典型的镇痛作用,表现出降低但明显的滥用潜力,并且在不超过镇痛范围的剂量下不会产生呼吸作用。SR 系列中的非典型 MOR 激动剂应作为更安全的镇痛药开发的基础分子进一步研究。